Abaloparatide is a 34-amino-acid synthetic peptide analog of parathyroid hormone-related protein (PTHrP) (MW ~3960.6 g/mol), FDA-approved in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It selectively activates the PTH1 receptor in its RG (guanine nucleotide-free) conformation, which favors anabolic bone-forming activity over bone resorption. Abaloparatide represents a differentiated approach from teriparatide, with potentially less bone resorption stimulation and lower hypercalcemia risk.
Category: Bone / PTH Analog. Evidence rating: A (strong human clinical data).
Clinical status: FDA-approved (Tymlos for postmenopausal osteoporosis, April 2017)
Abaloparatide is a PTHrP(1-34) analog that binds to the PTH type 1 receptor (PTH1R) with a preference for the RG conformation (guanine nucleotide-free state), which is associated with transient cAMP signaling that favors bone formation over bone resorption. This contrasts with teriparatide, which…
Research base: 0 registered clinical trials and 1 indexed publication reference Abaloparatide.
Safety considerations: Common (>=2%): hypercalciuria (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), fatigue (3%); Injection site reactions: erythema, edema, pain at injection site; Orthostatic hypotension: dizziness within 4 hours of dose, especially early in treatment.
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~3960.6 g/mol |
|---|---|
| CAS number | 247062-33-5 |
| Half-life | ~1.7 hours |
| Bioavailability | ~36% subcutaneous |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | FDA-approved. Tymlos (abaloparatide 80 mcg SC injection) approved April 2017 for postmenopausal osteoporosis at high fracture risk. |
Related peptides: Teriparatide, PTH (Parathyroid Hormone).
Compare: Abaloparatide vs PTH (Parathyroid Hormone).
Both are anabolic bone agents given as daily subcutaneous injections for osteoporosis. Abaloparatide is a PTHrP analog that preferentially activates the RG conformation of PTH1R, while teriparatide is a PTH(1-34) fragment. In the ACTIVE trial, abaloparatide produced numerically greater total hip BMD gains and had a lower hypercalcemia rate than teriparatide. Both have a 2-year cumulative use…
In preclinical studies, rats treated with high doses of abaloparatide (and teriparatide) for near-lifetime durations developed osteosarcoma. Although the relevance to humans at therapeutic doses is uncertain, the FDA requires a cumulative 2-year limit on parathyroid hormone analog therapy as a precaution.
An antiresorptive agent (typically a bisphosphonate like alendronate or denosumab) should be started after completing abaloparatide to consolidate and maintain the BMD gains. The ACTIVExtend trial demonstrated that alendronate after abaloparatide maintained fracture protection for at least 2 additional years.
Coverage on this site: Abaloparatide Reduces Osteoporotic Spine Fractures by 84%.